Access cutting-edge major depressive disorder treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access major depressive disorder specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related major depressive disorder treatment provided free
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, approximately 35 days 2. 42-day Treatment Period 3. 2-week post do
Sponsor: Autobahn Therapeutics, Inc.
Check if you qualify for this major depressive disorder clinical trial in Birmingham, AL
If you're searching for major depressive disorder treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced major depressive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.